Literature DB >> 34787833

Lead Exposure in Developmental Ages Promotes Aβ Accumulation by Disturbing Aβ Transportation in Blood-Cerebrospinal Fluid Barrier/Blood-Brain Barriers and Impairing Aβ Clearance in the Liver.

Can-Can Zhou1, Xu-Jie Wang1, Zi-Chen Li1, Wen-Jie Lu1, Yun-Ting Zhang1, Fu-Ming Shen2, Dong-Jie Li3.   

Abstract

Environmental lead exposure is closely related to the progression of Alzheimer's disease (AD). Our previous study has shown that exposure to lead could result in the cholesterol unbalance and increase amyloid-beta (Aβ) generation in the brain. However, the potential effect of lead exposure on Aβ transportation is poorly reported. In this study, we sought to explore whether lead exposure in developmental ages impaired the integrity of BCSFB and BBB, two highly vascularized structures in the brain in a rat model. The Aβ clearance in the liver was also assessed. Our results showed that lead treatment in developmental ages increased the number of TUNEL-positive apoptotic cells in rat choroid plexus and microvessels. Moreover, lead exposure markedly increased pro-inflammatory factors expression including TNF-α and IL-1β in rat choroid plexus and microvessels. Interestingly, lead treatment increased the expression of AQP-1 and reduced the expression of TTR, two key proteins associated with the functions of choroid plexus and microvessels. Additionally, the expressions of ABCB1, LRP-1, and RAGE, three major receptors responsible for Aβ transportation, were disturbed by developmental lead exposure. All these pathologies resulted in Aβ1-40 deposition within BCSFB and BBB and malfunctions of these two vascularized structures. Finally, we found that lead treatment remarkably inhibited the gene expression of LRP-1, which is responsible for Aβ endocytosis, in the liver tissue of the rat model. Collectively, our results provide the first evidence that developmental lead exposure induces Aβ deposition in BCSFB and BBB and impairs Aβ clearance in the liver, which would ultimately disturb Aβ transportation via choroid plexus/brain microvessels and facilitate Aβ deposition in the brain.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Amyloid-beta; Blood-cerebrospinal fluid barrier; Blood–brain barrier; Lead; Neurotoxicology

Mesh:

Substances:

Year:  2021        PMID: 34787833     DOI: 10.1007/s12011-021-02969-8

Source DB:  PubMed          Journal:  Biol Trace Elem Res        ISSN: 0163-4984            Impact factor:   3.738


  30 in total

1.  Blood-brain barrier permeability in Alzheimer's disease: a case-control MRI study.

Authors:  John M Starr; Andrew J Farrall; Paul Armitage; Brian McGurn; Joanna Wardlaw
Journal:  Psychiatry Res       Date:  2009-02-10       Impact factor: 3.222

2.  The cerebrospinal fluid production rate is reduced in dementia of the Alzheimer's type.

Authors:  G D Silverberg; G Heit; S Huhn; R A Jaffe; S D Chang; H Bronte-Stewart; E Rubenstein; K Possin; T A Saul
Journal:  Neurology       Date:  2001-11-27       Impact factor: 9.910

3.  GLUT1 reductions exacerbate Alzheimer's disease vasculo-neuronal dysfunction and degeneration.

Authors:  Ethan A Winkler; Yoichiro Nishida; Abhay P Sagare; Sanket V Rege; Robert D Bell; David Perlmutter; Jesse D Sengillo; Sara Hillman; Pan Kong; Amy R Nelson; John S Sullivan; Zhen Zhao; Herbert J Meiselman; Rosalinda B Wendy; Jamie Soto; E Dale Abel; Jacob Makshanoff; Edward Zuniga; Darryl C De Vivo; Berislav V Zlokovic
Journal:  Nat Neurosci       Date:  2015-03-02       Impact factor: 24.884

4.  Iron supplement prevents lead-induced disruption of the blood-brain barrier during rat development.

Authors:  Qiang Wang; Wenjing Luo; Wei Zheng; Yiping Liu; Hui Xu; Gang Zheng; Zhongming Dai; Wenbin Zhang; Yaoming Chen; Jingyuan Chen
Journal:  Toxicol Appl Pharmacol       Date:  2006-12-08       Impact factor: 4.219

5.  Neurogenic effects of β-amyloid in the choroid plexus epithelial cells in Alzheimer's disease.

Authors:  Marta Bolos; Carlos Spuch; Lara Ordoñez-Gutierrez; Francisco Wandosell; Isidro Ferrer; Eva Carro
Journal:  Cell Mol Life Sci       Date:  2013-03-03       Impact factor: 9.261

6.  Environmental exposure to lead and children's intelligence at the age of seven years. The Port Pirie Cohort Study.

Authors:  P A Baghurst; A J McMichael; N R Wigg; G V Vimpani; E F Robertson; R J Roberts; S L Tong
Journal:  N Engl J Med       Date:  1992-10-29       Impact factor: 91.245

Review 7.  Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis.

Authors:  George S Bloom
Journal:  JAMA Neurol       Date:  2014-04       Impact factor: 18.302

8.  Chrysophanol attenuates lead exposure-induced injury to hippocampal neurons in neonatal mice.

Authors:  Ji Zhang; Chunlin Yan; Shu Wang; Yong Hou; Guiping Xue; Li Zhang
Journal:  Neural Regen Res       Date:  2014-05-01       Impact factor: 5.135

Review 9.  The amyloid hypothesis of Alzheimer's disease at 25 years.

Authors:  Dennis J Selkoe; John Hardy
Journal:  EMBO Mol Med       Date:  2016-06-01       Impact factor: 12.137

10.  Metformin Ameliorates Aβ Pathology by Insulin-Degrading Enzyme in a Transgenic Mouse Model of Alzheimer's Disease.

Authors:  Xin-Yi Lu; Shun Huang; Qu-Bo Chen; Dapeng Zhang; Wanyan Li; Ran Ao; Feona Chung-Yin Leung; Zhimin Zhang; Jisheng Huang; Ying Tang; Shi-Jie Zhang
Journal:  Oxid Med Cell Longev       Date:  2020-04-19       Impact factor: 6.543

View more
  2 in total

1.  Zinc supplementation ameliorates sorafenib-induced cognitive impairment through ROS/JNK signaling pathway.

Authors:  Can-Can Zhou; Yu-Qiong He; Yu-Shuang Qiu; Chen-Xu Ni; Fu-Ming Shen; Dong-Jie Li
Journal:  Biol Trace Elem Res       Date:  2022-02-07       Impact factor: 3.738

2.  Effects of bacterial organic selenium, selenium yeast and sodium selenite on antioxidant enzymes activity, serum biochemical parameters, and selenium concentration in Lohman brown-classic hens.

Authors:  A I Muhammad; A M Dalia; T C Loh; H Akit; Anjas A Samsudin
Journal:  Vet Res Commun       Date:  2021-11-30       Impact factor: 2.459

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.